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Abstract
Background: Tumor invasiveness is directly related to the ability of tumor cells to migrate and invade surrounding
tissues, usually degrading extracellular matrix. Despite significant progress in the knowledge about migration and
invasion, there is much more to elucidate about their regulatory mechanisms, especially in cancer cells. MicroRNAs
(miRs) were recently described as important regulators of migration. Differential expression of miRs in cancer is
frequently associated with progression, invasion and metastasis. In papillary thyroid carcinoma (PTC), miR-146b-5p is
highly expressed and positively correlated to the degree of malignancy.
Methods: This study aimed to investigate the role of miR-146b-5p on the migratory and invasive behaviors of
thyroid cells, using a non tumor rat thyroid follicular cell line (PCCl3) transfected with the miR-146b-5p genomic
region, and two PTC cell lines (TPC-1 and BCPAP, bearing distinct oncogenic backgrounds), which express high
levels of miR-146b-5p, after miR-146b inhibition by antagomiR and miR-146b overexpression by mimics-miR.
Migration and invasion were studied by time-lapse and transwell assays (with and without Matrigel®). Gelatin
degradation assays were also employed, as well as F-actin staining.
Results: Migration and invasion of PCCl3 were increased 2-3x after miR-146b-5p overexpression (10X) and large
lamellipodia were evident in those cells. After miR-146b-5p inhibition, TPC-1 and BCPAP migration and invasion
were significantly reduced, with cells showing several simultaneous processes and low polarity. Gelatin degradation
was inhibited in TPC-1 cells after inhibition of miR-146b-5p, but was unaffected in BCPAP cells, which did not
degrade gelatin. The inhibition of miR-146b-5p in PCCl3 also inhibited migration and invasion, and additional
(exogenous) overexpression of this miR in TPC-1 and BCPAP cells increased migration and invasion, without effects
on cell morphology or gelatin degradation. The overexpression of SMAD4 in BCPAP cells, a validated target of
miR-146b-5p and key protein in the TGF-β signaling pathway, inhibited migration similarly to the effects observed
with the antagomiR 146b-5p.
Conclusions: miR-146b-5p positively regulates migration and invasion of thyroid normal and tumor follicular cells
(independently from their original mutation, either BRAF or RET/PTC), through a mechanism that involves the actin
cytoskeleton but not an increased capacity of matrix degradation.
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Background
Tumor invasiveness is directly related to the ability of
tumor cells to migrate and invade surrounding tissues,
spreading via blood and lymphatic circulation. In tumors,
the more pronounced is the migratory phenotype, the
higher is its metastatic potential [1]. A complex signal
transduction network involving different pathways directly
and indirectly controls tumorigenesis and invasion [2].
Highly invasive adherent tumor cells present a mesen-
chymal phenotype and are able to migrate faster, degrad-
ing extracellular matrix on their way. In general, in
order to migrate, these cells polarize and form lamelli-
podia at the cell front, which are large membrane pro-
jections rich in branching actin filaments and lacking
organelles. New adhesions to the extracellular matrix
(ECM) are established, and some of them mature to be-
come anchorage junctions to the actin cytoskeleton. Ad-
hesion maturation is followed by the pulling of the cell
body forward and retraction of the rear, partially due to
the contraction of actin-myosin II bundles present inside
the cell and in the cell cortex [3]. Sometimes filopodia,
which are thin spike-like exploratory processes, precede
or accompany lamellipodia formation. This migration
cycle is regulated by Rho GTPases, central modulators
of the cytoskeleton involved in many signaling pathways
[4]. The classic regulatory cycle of Rho GTPases involve
molecules that regulate GTP binding and hydrolysis, as
well as the availability of GTPases to be activated, usually
in cell membranes. In the last few years, other important
regulatory mechanisms were described, including micro-
RNAs (miRs) [5].
MicroRNAs are small, non-coding RNAs that regulate
protein expression and have been implicated in both the
promotion and suppression of metastasis [6]. The term
‘metastamir’ describes miRs that are involved in tumor
metastasis in different ways, acting either as prometa-
static or antimetastatic [7]. The role of miRs is post-
transcriptional gene regulation via perfect or imperfect
pairing with the 3’ untranslated region (UTR) of target
messenger RNAs (mRNAs), leading to mRNA degrad-
ation or translation blockage. In tumors, the differential
expression of miRs (up or down) is frequently associated
with progression, invasion and metastasis. For this rea-
son, miRs have been considered as potentially important
tumor hallmarks, and their deregulation is the focus of
studies that intend to find tools for early diagnosis, prog-
nosis, monitoring and treatment [6, 7].
An example of tumor which invasive behavior is much
less understood than its development is the Papillary
Thyroid Carcinoma (PTC). Both in tumor progression
and invasiveness, however, miRs are involved [8]. PTC is
the most common thyroid type of cancer, representing
about 80 % of all malignant tumors in this organ [9, 10].
It is usually a multifocal intra-thyroid tumor (65 % of
cases), which can be encapsulated or infiltrative. Small
localized PTCs show a 99 % survival rate at 20 years, be-
ing considered low risk cancers. Considering the scores
usually applied to classify PTCs as low risk, such as age,
grade, extent (invasiveness and distant metastasis), size,
sex and nodal spread, about 80–85 % of PTCs have ex-
cellent prognosis. These scores, however, are not suited
to predict tumor recurrence, which is common (up to
30 % of patients). PTC recurrence may occur up to
20 years after the initial diagnosis and is commonly asso-
ciated with cervical lymph node metastasis [11, 12].
Very important genetic alterations involved in PTC devel-
opment include RET/PTC rearrangements and BRAFV600E
mutation; RAS mutation is less common [13]. These mu-
tations constitutively activate the same signaling pathway,
and rarely overlap. The growth factor TGF-β is a negative
regulator of thyroid follicular cell growth, and the evasion
of TGF-β signaling by follicular thyroid cells results in in-
creased proliferation, the acquisition of an invasive pheno-
type and tumor progression [14, 15].
Several large-scale studies have shown deregulation
of miRs in thyroid tumor samples, when compared
to normal thyroid tissues [6, 16–23]. The miR146b-
5p has received great attention for being one of the
most expressed and positively correlated with tumor
aggressiveness and extra-thyroid invasiveness [24–26].
It has been investigated as a potential molecular
marker, but its functional roles are still poorly under-
stood [27, 28].
In this study, we aimed to investigate the influence of
miR-146b-5p on the migratory and invasive behaviors of
thyroid normal and tumor cells, in order to determine
its contribution to thyroid carcinoma invasiveness. Ex-
perimental procedures were performed with non-tumor
rat thyroid follicular cell line (PCCl3) and two PTC cell
lines (TPC-1 and BCPAP) after overexpression and in-
hibition of miR-146b-5p by specific oligonucleotides,
mimics-miR and antagomiR, respectively . Briefly, we
found that the overexpression of miR-146b-5p in PCCl3
increased migration and invasion, whereas an opposite
proportional effect was observed in PTC tumor cell lines
after miR-146b-5p inhibition. The inhibition of miR-
146b-5p in PCCl3 also inhibited migration and invasion,
and exogenous overexpression of this miR in TPC-1 and
BCPAP cells increased migration and invasion even
more. The overexpression of SMAD4 in BCPAP cells, a
validated target of miR-146b-5p and key protein in the
TGF-β signaling pathway, inhibited migration similarly
to the effects observed with the antagomiR 146b-5p.
Curiously, migration was equally affected in the presence
or absence of basement membrane (Matrigel®), and was
not related to the cell’s capacity to degrade ECM. These
results suggest that miR-146b-5p may be considered an
important prometastatic metastamiR in PTC.
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Fig. 1 (See legend on next page.)
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Results
Inhibition of miR-146b-5p decreases migration and
invasion of the human papillary thyroid carcinoma (PTC)
cell lines TPC-1 and BCPAP, whereas its overexpression
increases both processes
MiR-146b-5p, which has been positively correlated to
the degree of malignancy, is overexpressed in both hu-
man PTC cell lines, TPC-1 (spontaneously harboring the
RET/PTC-1 mutation) [29] and BCPAP (BRAFV600E
oncogene point mutation) [30]. A specific miR-146b-5p
oligonucleotide inhibitor (antagomiR) was used to re-
duce its expression in both cell lines (Figs. 1a and 2a)
before the transwell migration and invasion assays. The
results show that miR-146b-5p inhibition (~70 %) reduced
by at least 50 % the migration and invasion capacity of
TPC-1 (Fig. 1c and d) and BCPAP (Fig. 2c and d) cells.
This result was not influenced by differences in cell num-
ber, as shown by cell viability assays (Figs. 1b and 2b).
The overexpression of miR-146b-5p in TPC-1 and
BCPAP cells (by 11-12x), on the other hand, increased
migration and invasion by 2–2.5x in both cell lines
(Additional file 1: Figure S1).
MiR-146b-5p inhibition reduced gelatin degradation by
TPC-1, but not by BCPAP cell lines
In order to evaluate whether miR-146b-5p influences the
extracellular matrix degradation during the invasion
process, we used fluorescent gelatin degradation assays for
both tumor cell lines, as shown in Fig. 3. Curiously, only the
TPC-1 cell line degraded gelatin. After miR-146b-5p inhib-
ition, the substrate degradation activity of this cell line was
reduced to small focal points during the assay, very different
from the control groups (Fig. 3a). In BCPAP cell line, no dif-
ferences between controls and miR-146b-5p-inhibited
groups were observed (Fig. 3b). The overexpression of miR-
146b-5p in TPC-I cells led to a slight (not significant) in-
crease in gelatin degradation, whereas BCPAP cells were
still not able to degrade gelatin (Additional file 2: Figure S2).
MiR-146b-5p inhibition reduced cell polarization and
increased the number of cellular protrusions in TPC-1 and
BCPAP cell lines
In order to investigate the effects of miR-146b-5p inhibition
on cell morphology and actin cytoskeletal reorganization,
we stained the F-actin filaments in both tumor cell lines
using fluorescent phalloidin, as shown in Fig. 4. We ob-
served that control cells (which express high levels of
miR-146b-5p) were elongated, suggesting polarization,
featuring one or two predominant lamellipodia. Add-
itionally, BCPAP cells showed very large lamellipodia
and many filopodia. In contrast, both TPC-1 and
BCPAP cells with miR-146b-5p inhibited lost polarity,
showing several protrusions in different directions, ap-
parently smaller lamellipodia (Fig. 4). By time-lapse we
observed that many of these cells did not translocate ef-
fectively due to this poorly polarized phenotype (data
not shown).
Interestingly, the overexpression of miR-146b-5p in
TPC-1 and BCPAP cells did not affect cell morphology
or the F-actin distribution in both cell lines (Additional
file 3: Figure S3). Probably these highly migratory
cells were already optimized for effective migration,
showing distinct polarization and one or two large
lamellipodia.
Overexpression of miR-146b-5p in normal rat thyroid cell
line (PCCl3) increases migration and invasion, while its
inhibition inhibits both processes
Using a non tumor thyroid cell line (PCCl3) we aimed
to evaluate if the overexpression of miR-146b-5p influ-
ences migration and invasion per se. We transfected the
cells with a pcDNA3.1 plasmid containing the genomic
region of miR-146b-5p (PC-CMV-146b) [31]. As con-
trols, non transfected cells or cells transfected with the
empty vector (PC-CMW-ø) were used. MiR-146b-5p ex-
pression was measured by qPCR. The results show that
cells overexpressing miR-146b-5p (~10 times, Fig. 5a)
migrated and invaded about 3 times more than control
cells (Fig. 5c and d). No differences were observed in the
growth curve up to 72 h (Fig. 5b). F-actin staining
showed increased cell spreading, especially on Matrigel®,
as well as the presence of large lamellipodia and more
actin-myosin bundles (stress fibers) when compared to
control cells (Fig. 6). On the other hand, the inhibition
of miR-146b-5p by ~50–60 % using a specific antagomiR
also inhibited migration and invasion by approximately
50–60 % (Additional file 4: Figure S4).
(See figure on previous page.)
Fig. 1 Inhibition of miR-146b-5p decreases migration and invasion of the PTC cell line TPC-1. Cells were transfected with an oligonucleotide
antagomiR-146b-5p (Anti-146b) (30nM), as described in the Methods section. Three control groups were used: (1) cells cultured in regular culture
medium (identified as TPC-1), (2) cells incubated with the transfection agent only (Mock) and (3) cells transfected with a negative miR-control
(Neg). Forty-eight hours after transfection miR-146b-5p expression (a) and cell viability (b) were evaluated. Transwell migration (without basement
membrane) and invasion (with basement membrane) assays were performed for 8 h. Representative images and quantitative data are shown for
migration (c) and invasion assays (d). All experiments were performed three times. TPC-1: cell, Mock: cell + transfection agent, Neg: cell + anti-miR
negative control, Anti-146b: cell + anti-miR-146b-5p. Statistically significant differences: * P < 0,01 (TPC-1 versus Anti-146b); ** P < 0,01 (Mock versus
Anti-146b), *** P< 0,01 (Neg versus Anti-146b)
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Fig. 2 (See legend on next page.)
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Overexpression of SMAD4 in the BCPAP tumor cell line
decreases migration and invasion
BCPAP cells overexpressing SMAD4 were created by
using BCPAP-pBabe SMAD4 plasmid and its respective
control. The effectiveness of transfection was checked by
RT-PCR (3x increased in the mRNA) and by western
blotting (60 % increase in SMAD4 protein). BCPAP cells
express high levels of miR-146-5p, which reduces SMAD4
basal expression [31]. Cells transfected with SMAD4
showed a 60–70 % decrease in migration and invasion, an
effect very similar to the effect obtained after treatment
with the antagomiR (Fig. 7).
Discussion
A differential overexpression of miR-146b has been ob-
served in different types of cancer, not always correlated
with tumor progression or invasion [32–34]. Actually,
regarding invasiveness, the miR-146b has been consid-
ered inhibitory of migration and invasion in several types
of tumors, i.e. gliomas, lung cancer, pancreatic cancer,
and osteosarcoma [32–37]. On the other hand, the high
expression of miR-146b-5p in PTC has been positively
correlated with the malignancy and aggressiveness in
clinicopathological correlative studies [8, 38, 39]. It has
also been associated with a higher degree of extra-
thyroid invasiveness [10, 24–26]. Recently, using in vitro
wound healing assays, Wojtas et al. [40] showed that the
overexpression of miR-146b improved migration of
HTori-3 and FTC-133 cell lines. In gliomas, reduced ex-
pression of miR-146b contributes to increase MMP16
and promote metastasis [37]. In thyroid cancer cells, the
targeting of ZNFR3 by miR-146b stimulates Epithelial-
to-mesenchymal transition (EMT) [39]. Nevertheless,
the functional roles of miR-146b appear to affect differ-
ent cellular processes important for tumor development
and are still poorly understood.
In this study, we demonstrate that miR-146b-5p stim-
ulates the migratory and invasive behavior of PTC cell
lines. Overexpression of miR-146b-5p in a normal rat
thyroid cell line (PCCl3) led to increased spreading on
the substrate, formation of large lamellipodia, increased
migration (without exogenous basement membrane) and
invasion (in the presence of basement membrane). The
opposite effect was observed after the inhibition of this
miR in this cell line and also in human thyroid tumor
cell lines which, although bearing different mutations,
overexpressed miR-146b. Both TPC-1 and BCPAP cells
showed decreased migration and invasion, lacking direc-
tionality due to the formation of smaller protrusions in
different directions. Exogenous overexpression of miR-
146b-5p in both tumor cell lines increased migration
and invasion even more, without effects on cell morph-
ology or in the F-actin arrangement.
TPC-1 and BCPAP cells are highly migratory [41, 42].
In both tumor cell lines, our results showed a similar de-
gree of inhibition for migration and invasion, suggesting
that the effects of miR-146b-5p are mostly associated
with the cytoskeleton, and not necessarily related to in-
creased degradation of ECM. This hypothesis was fur-
ther confirmed by gelatin degradation assays, which
showed that only TPC-1 significantly degraded gelatin
under regular conditions. The inhibition of miR-146b-5p
significantly reduced this function in those cells, al-
though without any additional disadvantage to the cells
to migrate. Besides, it was interesting to observe that the
inhibition of migration was similar in both cell lines,
considering that their proteolytic capacities may be quite
different. The overexpression of miR-146b-5p slightly in-
creased gelatin degradation by TPC-1 cells, having no ef-
fect on BCPAP cells gelatinolytic activity.
In several carcinomas, different signaling pathways
such as TGF-β, Wnt-β-catenin and Notch are involved
in Epithelial-Mesenchymal Transition (EMT), a crucial
step for invasion of surrounding tissues [43]. SMAD4, a
crucial protein in the canonical TGF-β signaling path-
way, was validated as a target of miR-146b-5p in BCPAP,
TPC-1 and PCCl3 cells [31]. The authors showed that
miR-146b-5p targets the 3'UTR of SMAD4. Interest-
ingly, in PCCl3 normal thyroid cells the activation of the
oncogenes RET/PTC3 and BRAF upregulated miR-146b-
5p expression [31].
In thyroid gland homeostasis, TGF-β plays a crucial role
regulating thyrocyte growth and differentiation, together
with the thyroid-stimulating hormone [44]. Additionally,
the TGF-β pathway plays important roles in other cellular
functions, i.e. apoptosis and cell motility [15, 44, 45].
TGF-β is synthesized as an inactive precursor that can
be activated by different proteases produced by thyrocytes,
(See figure on previous page.)
Fig. 2 Inhibition of miR-146b-5p decreases migration and invasion of the PTC cell line BCPAP. Cells were transfected with an oligonucleotide
antagomiR-146b-5p (Anti-146b) (30nM), as described in the Methods section. Three control groups were used: (1) cells cultured in regular culture
medium (identified as BCPAP), (2) cells incubated with the transfection agent only (Mock) and (3) cells transfected with a negative miR-control
(Neg). Forty-eight hours after transfection miR-146b-5p expression (a) and cell viability (b) were evaluated. Transwell migration (without basement
membrane) and invasion (with basement membrane) assays were performed for 8 h. Representative images and quantitative data are shown for
migration (c) and invasion assays (d). All experiments were performed three times. BCPAP: cell, Mock: cell + transfection agent, Neg: cell + anti-miR
negative control, Anti-146b: cell + anti-miR-146b-5p. Statistically significant differences: * P < 0,01 (BCPAP versus Anti-146b); ** P < 0,01 (Mock
versus Anti-146b), *** P < 0,01 (Neg versus Anti-146b)
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antagonizing the mitotic effect of other growth factors
and hormones [44]. Briefly, the canonical signaling path-
way starts with TGF-β binding to its specific receptor type
II, which phosphorylates and activates type I receptor
(TBRI). TBRI propagates the signal through the activation
and phosphorylation of cytoplasmic proteins known as R-
SMADs (SMAD2 and SMAD3). SMAD4 combines the R-
SMADs and directs this complex to the nucleus, where it
will modulate transcription of the target genes. In thyroid
tumors, similarly to some other carcinomas, the sensitivity
Fig. 3 Inhibition of miR-146b-5p decreased gelatin degradation by TPC-1 cells. Forty hours after transfection, cells were seeded upon glass coverslips
(18 mm) coated with fluorescent gelatin (green) and cultured for 8 h. After this period, cells were fixed, stained for F-actin (red) and nucleus (blue) and
analyzed by confocal microscopy. Representative images are shown for TPC- 1 (a) and BCPAP (b) cells. The degradation activity of control and treated
groups (miR-146b-5p inhibited) are identified as dark areas on gelatin-FITC background. TPC-1 / BCPAP: cell, Mock: cell + transfection agent, Neg: cell +
anti-miR negative control, Anti-146b: cell + anti-miR-146b
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to TGF-β is lost during tumor development [45]. SMAD4
deficiency has been widely associated with TGF-β resist-
ance of tumor cells, contributing to accelerate the malig-
nant progression [44, 45]. This fact is not considered
essential for tumor initiation, but it has been proven that
in its absence, the development of a more aggressive
phenotype occurs [31, 46].
Our hypothesis is that miR-146-5p contributes to regu-
late cell migration and invasion through the targeting of
SMAD4 in normal and tumor thyroid cell lines. Reinfor-
cing this hypothesis, D’Inzeo et al. [47] have shown that in
TPC-1 and BCPAP cells, characterized by a significant re-
duction in the level of SMAD4 protein, the overexpression
of SMAD4 partially reestablishes TGF-β responsiveness
and significantly reduces migration, showing that SMAD4
is a critical regulator of this process. The overexpression
of SMAD4 in BCPAP cells significantly decreased migra-
tion and invasion to a degree very similar to that observed
with the antagomiR 146-5p, suggesting that SMAD4 is, in-
deed, a very important target of miR-146b-5p in those
cells, regulating cell migration.
Conclusion
Our findings improve the understanding of the func-
tional role of miR-146b-5p in thyroid gland oncogenesis.
The regulatory capacity of miR-146b-5p on tumor inva-
sion, possibly through SMAD4 and the impairment of
TGF-β signaling, shows its important role on PTC ag-
gressiveness and invasiveness. This study also shows that
Fig. 4 Inhibition of miR-146b-5p alter F-actin cytoskeleton distribution and cell morphology. Forty hours after transfection, cells were seeded
upon glass coverslips (18 mm) without and with Matrigel® coating (10 μg/ml) and cultured for 8 h. After this period, cells were fixed, stained for
F-actin (green) and nucleus (blue) and analyzed by confocal microscopy. Representative images of TPC-1 (a) and BCPAP cells (b) are shown. For
both cell lines, control cells (TPC-1/BCPAP, Mock and Neg) are polarized and show one or two predominant lamellipodia, whereas cells with inhib-
ition of miR-146b-5p (Anti-146B) show a higher number of smaller protrusions in different directions. TPC-1/BCPAP: cell, Mock: cell + transfection
agent, Neg: cell + anti-miR negative control, Anti-146b: cell + anti-miR-146b. Bars: 10 μm
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the role of miR-146b-5p is independent of the cell’s cap-
acity to degrade ECM.
Methods
Cell lines and cell culture
Non tumor rat follicular cells (PCCL3) and human papil-
lary thyroid carcinoma cell lines TPC-1 (spontaneously
harboring RET/PTC-1 mutation) and BCPAP (BRAFV600E
oncogene) were provided by Professor Edna T. Kimura.
Culture conditions and supplements for each cell line
were performed as previously described [48]. Briefly,
PCCl3 were cultured in Coon's F12 medium supple-
mented with 5 % fetal bovine serum (FBS), penicillin (100
U / ml) and streptomycin (100 mg / ml), amphotericin
(1 μg/ml) and thyroid stimulating hormone stimulant (1U
/ ml), bovine transferrin (5 g / ml), hydrocortisone (10
nM) and insulin (10 / ml). TPC-1 and BCPAP were cul-
tured in DMEM medium supplemented with 5 % and
10 % FBS respectively, 100 U / ml penicillin, 1 μg/ml
streptomycin and 100 μg/ml amphotericin at 37 °C and
5 % CO2 atmosphere.
Plasmids and transfections
PCCl3 were transfected with a pcDNA3.1 plasmid con-
taining the genomic region of miR-146b-5p (PC-CMV-
146b) or the pcDNA3.1 empty vector (PC-CMV- ø as
control), as previously described [31]. Inhibition of
miR-146b-5p in PCCl3 and PTC cell lines (highly
expressed) was obtained with the use of antagomiR-
146b-5p (30nM -Anti-miR TM miRNA Inhibitor Product
Anti-hsa-miR-146b-5p, AM10105, Applied Biosystems,
Foster City, CA, USA), transfected with Lipofectamine
2000. The overexpression of miR-146b-5p of PTC cell
lines was performed by mimics miR-146b-5p (50nM,
MirVana miRNA mimic has-miR-146b-5p, MC10105)
transfection.
Fig. 5 Overexpression of miR-146b-5p promotes migration and invasion of non tumor rat thyroid follicular cell line (PCCl3). Cells overexpressing
miR-146-5p (PC-CMV-146b) and control groups (PC-CMV-ø and PCCl3-WT) were cultured and submitted to transwell migration and invasion assays
for 24 h. After this period, miR-146b-5p expression (a) and cell viability (b) were evaluated. Representative images and quantitative data for migra-
tion (c) and invasion (d) assays are shown. PCCl3-WT: normal thyroid follicular cell line, PC-CMV-ø: cell transfected with an empty vector, PC-CMV-
146b: cell transfected with the miR-146-5p genomic region. Statistically significant differences: * P < 0,01 (PCCl3-WT versus PC-CMV-146b); ** P <
0,01 (PC-CMV-ø and PC-CMV-146b)
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As controls, all cell lines were used in regular culture
conditions, incubated with transfection reagent alone
(Mock) or transfected with a commercially available
negative control (Negative) (anti-miR Negative con-
trol#1, AM17010; MirVana miRNA mimic negative Con-
trol#1, 4464058, Applied Biosystems).
BCPAP-pBabe SMAD4 and BCPAP-pBabe-puro were
created by transfecting the plasmids pBabe-puro-Smad4-
Flag and pBABE-puro plasmids, respectively, into
BCPAP cells. pBabe-puro-Smad4-Flag was a gift from
Sam Thiagalingam (Addgene plasmid # 37041) and
pBABE-puro was a gift from Hartmut Land & Jay Mor-
genstern & Bob Weinberg (Addgene plasmid # 1764)
[48, 49].
Quantitative PCR and miR-146b-5p mature miR
quantification
Total RNA from cell lines was isolated with Trizol, ac-
cording to the manufacturer's protocol (Invitrogen). For
miR expression analysis, the TaqMan microRNA Reverse
Transcription kit and RT Primers provided with the
miR-146b-5p Taqman miR Assay (PN4373178; Applied
Biosystems) were used according to the manufacturer’s
instructions to cDNA synthesis from total RNA (10 ng).
Subsequently, miR-146b-5p expression was detected
from the cDNA product using TaqMan Universal PCR
Master Mix No AmpErase UNG (Applied Biosystems)
and Taqman miR Assay according to the manufacturer’s
instructions (Applied Biosystems, Weiterstadt, Germany)
by qPCR. As housekeeping controls, small nucleolar
RNA - snoRNA (PN4427975; Applied Biosystems) and
RNU6B (PN4427975, Applied Biosystems) were used for
rat and human miR normalization, respectively.
For SMAD4 expression analysis, 1 μg of total RNA
was reverse transcribed using M-MLV Reverse Tran-
scription (Invitrogen) according to the Manufacturer’s
protocol, and PCR product was amplified from cDNA
using 1X SYBR Green Universal Master Mix (Applied
Biosystems) and specific primer. RPL19 was used as an
endogenous control from mRNA normalization. Data
were acquired using ABI 7300 Real-Time PCR System
(Applied Biosystems) and analyzed using the Q-Gene
Program.
Migration and invasion assays
Migration and invasion assays were performed using
transwell chambers with membrane pore size of 8.0 μm
(Corning Inc). Membranes were uncoated for the migra-
tion assays and coated with 25 μg Matrigel® (BD Biosci-
ences) for invasion assays. They were incubated with
PBS (migration) or Matrigel® during 1 h at 37 °C, 5 %
CO2 atmosphere. About 5 × 10
4 cells were suspended in
culture medium containing 0,5 %-1 % FBS and plated in
the upper chamber, whereas the lower chamber con-
tained culture medium with 5 %-10 % FBS. After 8 h
(TPC-1 and BCPAP cell lines) or 24 h (PCCl3 cell line)
at 37 °C, 5 % CO2, non-migrating cells on the top cham-
ber were removed using a cotton swab, and cells that
Fig. 6 Overexpression of miR-146b-5p enhances cell spreading and formation of large lamellipodia in non tumor rat thyroid follicular cell line
(PCCl3). Cells were seeded upon glass coverslips (18 mm) without and with Matrigel® coating (10 μg/ml) and cultured for 24 h. After this period,
cells were fixed, stained for F-actin (green) and nucleus (blue) and analyzed by confocal microscopy. PCCl3-WT: non tumor rat thyroid follicular cell
line, PC-CMV-ø: cell transfected with an empty vector, PC-CMV-146b: cell transfected with the miR-146-5p genomic region. Bars: 10 μm
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migrated through the membrane were fixed (4 % para-
formaldehyde - PFA in PBS) and stained with 0.5 %
Crystal Violet. Cells were photographed using a Nikon
Eclipse E600 microscope equipped with optical camera
CF160 epi-fluorescence and counted (10 representative
fields).
Growth curve
Non tumor rat follicular thyroid cells (10 × 104) were
seeded in 35 mm Petri dishes and cultured for 24, 48
and 72 h and after antagomiR transfection, PTC (TPC-I
and BCPAP) cell lines (1 x104) were seeded after 40 h
(0 h) and cultured for 8 and 24 h. At each time point
the cells were trypsinized, collected, stained with Trypan
Blue and the viable cells were counted using a Neubauer
chamber. Each assay was performed in triplicate and re-
peated 3 times for each sample.
Analysis of the F-actin cytoskeleton and time-lapse
Cells were seeded on glass coverslips (18 mm) with or
without Matrigel® coating (10 μg/ml), positioned in 12-
well plates and cultured for 8 h (PTC cell lines) or 24 h
(PCCl3). Cells were then fixed and permeabilized with
4 % PFA containing 0.5 % Triton X-100 and 5 % sucrose,
in PHEM buffer (25 mM Hepes, 10 mM EGTA, 2 mM
MgCl2, 60 mM Pipes, pH 6,9) for 5 min, and post-fixed
with 4 % PFA containing 5 % sucrose in PHEM buffer
for 30 min at room temperature. F-actin was stained
with phalloidin-Alexa 488 or rhodamine (Invitrogen)
(1:500) for 1 h. After three washes (PHEM/100 mM gly-
cine), the coverslips were mounted with Vectashield
containing DAPI, for nuclei staining. Images were ob-
tained using a Zeiss LSM780 Confocal Microscope with
a Multiphoton laser (Spectraphysics), at the Central Fa-
cility CEFAP-USP. Objectives C-Apochromat 63x/1.2 W
Corr M27 (D = 0.14–0.19 mm) (WD = 0.28 mm at D =
0.17 mm) and 40x/1.2 W (D = 0.14–0.19 mm) (WD =
0.28 mm at D = 0.17 mm) were employed. Live cells
plated on uncoated or Matrigel®-coated glass-bottomed
dishes were observed under phase contrast during 16 h
using the same equipment, at 37 °C and 5 % CO2.
Fluorescent substrate degradation assay
After 40 h of antagomiR-146b-5p transfection, PTC cell
lines were plated on coverslips coated with gelatin-FITC
(Invitrogen) and cultured for 24 h. Cells were then fixed
Fig. 7 Overexpression of SMAD4 decreases migration and invasion of BCPAP cells. Cells were transfected with pBabe-puro-Smad4-Flag and
pBABE-puro plasmids (control) as described in the Methods section. a The SMAD4 gene expression was analyzed by qPCR. RPL19 gene expression
was used for normalization. b, c Transwell migration (without basement membrane) and invasion (with basement membrane) assays were
performed during 8 h. pBabe ø: BCPAP transfected with pBABE-puro plasmids; pBabe SMAD4: BCPAP transfected with pBabe-puro-Smad4-Flag. d
For SMAD4 protein expression, 50 μg of total protein per sample were used. α -Tubulin expression was used for normalization. Statistically significant
differences: * P< 0,01 (pBabe SMAD4 versus pBabe ø)
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and F-actin was stained as previously described. F-actin
and gelatin degradation areas were analyzed and photo-
graphed using a Zeiss LSM780 Confocal Microscope
with a Multiphoton laser (Spectraphysics), at the Central
Facility CEFAP-USP. Substrate degraded areas were
measured using the Image J public software (NIH). The
same assays were performed after overexpression of
miR-146b-5p in both tumor cell lines for 8 h.
Protein expression analyses
BCPAP-pBabe SMAD4 and BCPAP-pBabe-puro were
seeded (1 × 106 cells), tripsinized and lysed in presence
of cocktail proteases inhibitors. Total protein (50 μg)
were separated by 10 % polyacrilamide gel electrophor-
esis (PAGE) and transferred onto nitrocellulose mem-
branes (Cat # 162–0115, Bio Rad). Membranes were
incubated with monoclonal anti-SMAD4 antibody (sc-
7966) from Santa Cruz Biotecnology Inc, and visualized
using an Enhanced ChemoLuminescence kit (Clarity
TM Western ECL Substrate, Cat # 170–5061, Bio Rad),
according to the manufacturer’s instructions. The poly-
clonal anti-alpha tubulin antibody (ab4074, ABCAM)
was used to normalize the protein expression.
Statistical analysis
The GraphPad Prism (version 5.0) program was used for
statistical analysis. Student’s t-test or two-way ANOVA
followed by Tukey’s post-test were used, according to
the comparison. Differences were considered statistically
significant at P < 0.05.
Additional files
Additional file 1: Figure S1. Overexpression of miR-146b-5p increases
migration and invasion of the PTC cell lines, TPC-1 and BCPAP. Cells were
transfected with an oligonucleotide mimics miR-146b-5p (miR-146b)
(50nM), as described in the Methods section. Three control groups were
used: (1) cells cultured in regular culture medium (identified as TPC-1,
BCPAP), (2) cells incubated with the transfection agent only (Mock) and
(3) cells transfected with a negative miR-control (Neg). Forty-eight hours
after transfection miR-146b-5p expression (A, D) was evaluated. Transwell
migration (without basement membrane) and invasion (with basement
membrane) assays were performed during 8 h. Quantitative data are
shown for migration (B, E) and invasion assays (C, F). All experiments were
performed three times. TPC-1/BCPAP: cell, Mock: cell + transfection agent, Neg:
cell +mimics-miR negative control, miR-146b: cell +mimics miR-146b-5p. Sta-
tistically significant differences: * P< 0,01 (TPC-1/BCPAP versus miR-146b); ** P
< 0,01 (Mock versus miR-146b), *** P> 0,01 (Neg versus miR-146b). (TIF
521 kb)
Additional file 2: Figure S2. Overexpression of miR-146b-5p slightly
increases gelatin degradation by TPC-1 cells. Forty hours after transfec-
tion, cells were seeded upon glass coverslips (18 mm) coated with fluor-
escent gelatin and cultured for 8 h. After this period, cells were fixed,
stained for F-actin and nucleus. Images (30) were obtained using fluores-
cence microscopy (60x objective) and cells with and without degradation
areas were counted. Data are shown for TPC-1 (A) and BCPAP (B) cells.
The degradation activity of control and treated groups (miR-146b-5p)
were identified as dark areas on gelatin-FITC background. TPC-1 / BCPAP:
cell, Mock: cell + transfection agent, Neg: cell + mimics miR negative
control, miR-146b: cell + mimics-miR-146b.
(TIF 279 kb)
Additional file 3: Figure S3. Overexpression of miR-146b-5p in TPC-1
and BCPAP cells does not affect morphology and F-actin distribution.
Forty hours after transfection, cells were seeded upon glass coverslips
(18 mm) without and with Matrigel® coating (10 μg/ml) and cultured for
8 h. After this period, cells were fixed, stained for F-actin (green) and
nucleus (blue) and analyzed by confocal microscopy. Representative
images of TPC-1 and BCPAP cells are shown. Cells are polarized and show
one or two predominant lamellipodia. TPC-1/BCPAP: cell, Mock: cell +
transfection agent, Neg: cell + mimics-miR negative control, miR-146b:
cell + mimics-miR-146b. Bars: 10 μm. (TIF 1884 kb)
Additional file 4: Figure S4. Inhibition of miR-146b-5p decreases
migration and invasion of the non tumor rat thyroid follicular cell line
(PCCl3). Cells were transfected with an oligonucleotide antagomiR-146b-5p
(Anti-146b) (0.5 and 1nM), as described in the Methods section. Three
control groups were used: (1) cells cultured in regular culture medium
(identified as PCCl3), (2) cells incubated with the transfection agent only
(Mock) and (3) cells transfected with a negative miR-control (Neg). Sixty-four
hours after transfection miR-146b-5p expression (A) was evaluated. Transwell
migration (without basement membrane) and invasion (with basement
membrane) assays were performed during 24 h, forty hours after trans-
fection. Quantitative data are shown for migration (B) and invasion as-
says (C). PCCl3: cell, Mock: cell + transfection agent, Neg: cell + anti-miR
negative control, Anti-146b: cell + anti-miR-146b-5p. Statistically significant
differences: * P < 0,05 (PCCl3 versus Anti-146b-1nM); ** P <0,05 (Mock versus
Anti-146b-1nM), *** P < 0,05 (Neg versus Anti-146b-1nM). (TIF 269 kb)
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